Retracing our STEP towards a successful CTL-based HIV-1 vaccine

Vaccine

Volumn 26, Issue 25, 2008, Pages 3138-3141

  Yang, Otto O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANTIGEN RECOGNITION; ANTIVIRAL ACTIVITY; ARTICLE; CELL MIGRATION; CLINICAL RESEARCH; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; LYMPHOCYTE MIGRATION; NONHUMAN; PRIORITY JOURNAL; TREATMENT FAILURE; VACCINATION; VACCINE PRODUCTION;

EID: 44749084067     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.02.027     Document Type: Note

References (42)

1. Vaccination and enrollment are discontinued in phase II trials of Merck's investigational HIV Vaccine Candidate. In: Press release from Merck and the HIV Vaccine Trials Network. Whitehouse Station NJ and Seattle, WA, 2007.
2. Moore C.B., John M., James I.R., Christiansen F.T., Witt C.S., and Mallal S.A. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296 5572 (2002) 1439-1443
3. + T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 79 21 (2005) 13239-13249
4. Liu Y., McNevin J., Cao J., Zhao H., Genowati I., Wong K., et al. Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol 80 19 (2006) 9519-9529
5. Matano T., Shibata R., Siemon C., Connors M., Lane H.C., and Martin M.A. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol 72 1 (1998) 164-169
6. Jin X., Bauer D.E., Tuttleton S.E., Lewin S., Gettie A., Blanchard J., et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 189 6 (1999) 991-998
7. + lymphocytes. Science 283 5403 (1999) 857-860
8. Dubey S., Clair J., Fu T.M., Guan L., Long R., Mogg R., et al. Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr 45 1 (2007) 20-27
9. Fu T.M., Dubey S.A., Mehrotra D.V., Freed D.C., Trigona W.L., Adams-Muhler L., et al. Evaluation of cellular immune responses in subjects chronically infected with HIV type 1. AIDS Res Hum Retroviruses 23 1 (2007) 67-76
10. Yang O.O. Will we be able to 'spot' an effective HIV-1 vaccine?. Trends Immunol 24 2 (2003) 67-72
11. + T-cell recognition of simian immunodeficiency virus-infected cells expressing the same variant sequences. J Virol 82 1 (2008) 575-581
12. Pantaleo G., and Koup R.A. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 10 8 (2004) 806-810
13. Betts M.R., Exley B., Price D.A., Bansal A., Camacho Z.T., Teaberry V., et al. Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci USA 102 12 (2005) 4512-4517
14. + cells. Virology 225 1 (1996) 248-253
15. + cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol 71 4 (1997) 3120-3128
16. Bennett M.S., Ng H.L., Dagarag M., Ali A., and Yang O.O. Epitope-dependent avidity thresholds for cytotoxic T-lymphocyte clearance of virus-infected cells. J Virol 81 10 (2007) 4973-4980
17. Bennett M.S., Ng H., Ali A., and Yang O.O. Cross-clade detection of HIV-1-specific CTL does not reflect cross-clade antiviral activity. J Infect Dis 197 3 (2008) 390-397
18. Shiver J.W., and Emini E.A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 55 (2004) 355-372
19. Kim M., Moon H.B., Kim K., and Lee K.Y. Antigen dose governs the shaping of CTL repertoires in vitro and in vivo. Int Immunol 18 3 (2006) 435-444
20. Alexander-Miller M.A., Leggatt G.R., and Berzofsky J.A. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA 93 9 (1996) 4102-4107
21. Byers D.E., and Lindahl K.F. Peptide affinity and concentration affect the sensitivity of M3-restricted CTLs induced in vitro. J Immunol 163 6 (1999) 3022-3028
22. + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200 6 (2004) 749-759
23. + T cell depletion and viral replication in SIV infection. Science 280 5362 (1998) 427-431
24. + T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 200 6 (2004) 761-770
25. + T-lymphocyte responses in blood and mucosa during chronic infection. J Virol 79 7 (2005) 4289-4297
26. + T-cell responses in rectal mucosa and peripheral blood mononuclear cells during chronic HIV type 1 infection. J Virol 81 11 (2007) 5460-5471
27. Ghendon Y., and Robertson S.E. Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Bull World Health Org 72 6 (1994) 973-983
28. Onorato I.M., Modlin J.F., McBean A.M., Thoms M.L., Losonsky G.A., and Bernier R.H. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J Infect Dis 163 1 (1991) 1-6
29. + T cell responses associated with control of viremia. Science 278 5342 (1997) 1447-1450
30. Kalams S.A., Buchbinder S.P., Rosenberg E.S., Billingsley J.M., Colbert D.S., Jones N.G., et al. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol 73 8 (1999) 6715-6720
31. McMichael A.J., and Phillips R.E. Escape of human immunodeficiency virus from immune control. Annu Rev Immunol 15 (1997) 271-296
32. Yang O.O. CTL ontogeny and viral escape: implications for HIV-1 vaccine design. Trends Immunol 25 3 (2004) 138-142
33. Yang O.O., Sarkis P.T., Ali A., Harlow J.D., Brander C., Kalams S.A., et al. Determinants of HIV-1 mutational escape from cytotoxic T lymphocytes. J Exp Med 197 10 (2003) 1365-1375
34. + lymphocytes in vivo. AIDS 11 Suppl A (1997) S17-S24
35. Brander C., and Riviere Y. Early and late cytotoxic T lymphocyte responses in HIV infection. AIDS 16 Suppl 4 (2002) S97-S103
36. Goulder P.J., Altfeld M.A., Rosenberg E.S., Nguyen T., Tang Y., Eldridge R.L., et al. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med 193 2 (2001) 181-194
37. + T cell immunity and viral escape following acute HIV-1 infection. J Immunol 171 7 (2003) 3837-3846
38. Borrow P., Lewicki H., Wei X., Horwitz M.S., Peffer N., Meyers H., et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 3 2 (1997) 205-211
39. + T cell frequencies. J Infect Dis 190 4 (2004) 713-721
40. Price D.A., Goulder P.J., Klenerman P., Sewell A.K., Easterbrook P.J., Troop M., et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci USA 94 5 (1997) 1890-1895
41. + cytotoxic T lymphocyte response. J Exp Med 200 10 (2004) 1243-1256
42. Karlsson A.C., Iversen A.K., Chapman J.M., de Oliviera T., Spotts G., McMichael A.J., et al. Sequential broadening of CTL responses in early HIV-1 infection is associated with viral escape. PLoS ONE 2 (2007) e225